BIP Asia 2017

2017年12月7日

Our recently created Chau Eagle Global IP had a successful exhibition at the BIP Asia 2017.

Chau Eagle Global IP is a merged practice between two top tier IP boutiques, Eagle IP in HK and F. Chau & Associates in New York. F. Chau & Associates, has been ranked No. 1 in New York (and No. 6 in the United States) for patent quality in consumer electronics by Ocean Tomo.

我们的过去活动

Eagle IP Celebrates 20th Anniversary, Reflecting on Two Decades of Excellence

2025年5月21日

Eagle IP is Coming Back to LSPN in Boston!

2025年4月24日

AIPLA Women in IP Global Networking Event in Hong Kong

2025年4月3日

Talk at Hong Kong Christian Service

2024年10月31日

Talk for HKUST Entrepreneurship 101 Training Program

2024年10月31日

IP Training Programme on patent commercialization and technology transfer

2024年10月8日

Recommended Insights

China’s Supreme People’s Court (SPC) Hands Down First Patent Linkage Appeal Decision

2022年9月21日

China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage. Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]

What Kind of Damage Awards Can You Get in China?

2022年6月16日

Is it worth filing for a patent in China? What kind of damage awards can you get? Pharma companies care more about injunction than damage awards, since it’s quite unlikely that any damage award can compensate for the large amounts of money that may be lost for patent infringement. Chinese courts often issue injunctions in […]

Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?

2020年7月14日

This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and […]

Burden Shift: CNIPA Requires Applicant to “Prove” that Post-Filing Data is not Fake Data

2025年4月1日

“Good Faith” is a challenging concept that brings with it the nuances of a particular jurisdiction’s ideas about honesty, moral values, and societal expectations. Most patent laws around the world include good faith requirements – especially in matters involving the legal and the medical profession – and China is no exception. So what’s the standard? […]